Asia Pacific – Clinical Value of Diagnostics https://clinicalvalue.com Thu, 27 Mar 2025 04:49:19 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://i0.wp.com/clinicalvalue.com/wp-content/uploads/2023/01/apple-touch-icon.png?fit=32%2C32&ssl=1 Asia Pacific – Clinical Value of Diagnostics https://clinicalvalue.com 32 32 225041835 APASL 2023 Taiwan Congress Report https://clinicalvalue.com/apasl-2023-taiwan-congress-report/ Wed, 31 May 2023 01:53:42 +0000 https://clinicalvalue.com/?p=6924 Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease. ...

The post APASL 2023 Taiwan Congress Report appeared first on Clinical Value of Diagnostics.

]]>

The post APASL 2023 Taiwan Congress Report appeared first on Clinical Value of Diagnostics.

]]>
6924
Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region https://clinicalvalue.com/utility-of-combining-pivka-ii-and-afp-in-the-surveillance-and-monitoring-of-hepatocellular-carcinoma-in-the-asia-pacific-region/ Fri, 17 Mar 2023 07:50:43 +0000 http://apac-clinicalvalue-prod-lb-800083143.ap-southeast-1.elb.amazonaws.com/?p=6242 A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements....

The post Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

A panel of 17 experts from the Asia-Pacific region reached a consensus on the clinical usefulness of protein-induced vitamin K absence II (PIVKA-II) for the surveillance and treatment monitoring of hepatocellular carcinoma (HCC). The experts agreed that PIVKA-II could be valuable in the detection of HCC in AFP-negative patients and for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence. However, more evidence is required for the combined use of PIVKA-II with ultrasound and AFP for HCC surveillance, including small HCC. Implementing PIVKA-II in the region will also have challenges, such as standardizing cut-off values, cost-effectiveness, and improving awareness among healthcare providers.

The post Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region appeared first on Clinical Value of Diagnostics.

]]>
6242
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update https://clinicalvalue.com/apac-hcc-guideline-2017-update-management-practices/ Tue, 14 Mar 2023 09:09:45 +0000 https://clinicalvalue.com/?p=6506 These latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK...

The post Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.

Authors: Masao Omata, Ann-Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei-Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir Dokmeci, and Shiv Kumar Sarin

The post Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update appeared first on Clinical Value of Diagnostics.

]]>
6506